✦ LIBER ✦

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

✍ Scribed by Hart, S.; Novotny-Diermayr, V.; Goh, K. C.; Williams, M.; Tan, Y. C.; Ong, L. C.; Cheong, A.; Ng, B. K.; Amalini, C.; Madan, B.; Nagaraj, H.; Jayaraman, R.; Pasha, K. M.; Ethirajulu, K.; Chng, W. J.; Mustafa, N.; Goh, B. C.; Benes, C.; McDermott, U.; Garnett, M.; Dymock, B.; Wood, J. M.

Book ID: 118229301
Publisher: American Association for Cancer Research
Year: 2012
Tongue: English
Weight: 971 KB
Volume: 12
Category: Article
ISSN: 1535-7163
DOI: 10.1158/1535-7163.mct-12-0466

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dietary flavonoid fisetin: A novel dual

Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management

✍ Vaqar Mustafa Adhami; Deeba Nadeem Syed; Naghma Khan; Hasan Mukhtar 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 348 KB

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor,

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

✍ Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.A.; Valero, V.; Guzman, M. 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 682 KB

320 Identification of potent, selective,

320 Identification of potent, selective, soluble and permeable small molecule PI3 kinase inhibitors for the treatment of cancer

✍ K. Ahmadi; W. Alderton; I. Chuckowree; P. Depledge; A. Folkes; G. Pergl-Wilson; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 283 KB

52 Discovery of novel fused thiadiazoles

52 Discovery of novel fused thiadiazoles as potent inhibitors of phosphoinositide-3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR)

✍ J. Pastor; G. Kurz; M.R. Rico Ferreira; D. Soilan; M.A. Ortega; S. Martinez; O. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

221 POSTER A novel inhibitor of phosphoi

221 POSTER A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancer

✍ K.R. Auger; L. Luo; S. Knight; G. Van Aller; P.J. Tummino; R.A. Copeland; M. Dia 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI